Hepatitis E: a neglected threat.
Hepatitis E, responsible for explosive waterborne outbreaks and sporadic cases of acute hepatitis in developing countries, affects predominantly young adults and has a fatality rate as high as 25% in pregnant women. No effective treatment exists for hepatitis E; however, a vaccine using a baculovirus-expressed recombinant hepatitis E capsid protein was recently studied in Nepal. In this review, the progress made in hepatitis E research and the recently concluded vaccine trial of the recombinant protein vaccine are briefly discussed.
Department of Virology, Armed Forces Research Institute of Medical Sciences, 315/6 Rajvithi Road, Bangkok 10400, Thailand. myintk@afrims.org
Khin Saw Aye
KS
Myint
Robert V
RV
Gibbons
D000328:Adult; D002986:Clinical Trials as Topic; D003906:Developing Countries; D019353:Endemic Diseases / Q000517:prevention & control; D005260:Female; D016751:Hepatitis E / Q000453:epidemiology* / Q000517:prevention & control; D016752:Hepatitis E virus / Q000276:immunology; D006801:Humans; D008297:Male; D014761:Viral Hepatitis Vaccines / Q000627:therapeutic use*
D014761:Viral Hepatitis Vaccines